BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 234 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.15 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $2,039,495 | +2.9% | 289,701 | +21.9% | 0.01% | 0.0% |
| Q1 2023 | $1,981,709 | -8.2% | 237,615 | +26.4% | 0.01% | -12.5% |
| Q4 2022 | $2,158,229 | +3.6% | 187,999 | +13.7% | 0.01% | 0.0% |
| Q3 2022 | $2,083,000 | -21.1% | 165,341 | -33.8% | 0.01% | -20.0% |
| Q2 2022 | $2,641,000 | +14.1% | 249,639 | +75.3% | 0.01% | +42.9% |
| Q1 2022 | $2,315,000 | -29.2% | 142,377 | -39.7% | 0.01% | -22.2% |
| Q4 2021 | $3,272,000 | +23.1% | 236,217 | +27.8% | 0.01% | +12.5% |
| Q3 2021 | $2,657,000 | -2.8% | 184,890 | +6.9% | 0.01% | -11.1% |
| Q2 2021 | $2,734,000 | +168.8% | 172,901 | +72.9% | 0.01% | +125.0% |
| Q1 2021 | $1,017,000 | – | 100,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VHCP Management, LLC | 1,744,356 | $18,455,000 | 9.59% |
| RA Capital Management | 4,347,456 | $45,996,000 | 3.30% |
| Cormorant Asset Management, LP | 1,168,000 | $12,357,000 | 2.84% |
| Baker Brothers Advisors | 5,867,031 | $62,073,000 | 0.79% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 907,920 | $9,606,000 | 0.39% |
| QVT Financial LP | 525,734 | $5,562,000 | 0.32% |
| EAM Investors, LLC | 114,548 | $1,212,000 | 0.22% |
| FRANKLIN STREET ADVISORS INC /NC | 93,000 | $984,000 | 0.20% |
| THB ASSET MANAGEMENT | 301,529 | $3,190,000 | 0.19% |
| TPG Group Holdings (SBS) Advisors, Inc. | 1,162,269 | $12,297,000 | 0.13% |